Please assess the completion status of the following clinical trial:

Trial Title: Oral Nutritional Supplement in Reducing Surgical Site Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for elective lower limb revascularization surgery~* patients aged \>18 years.~Exclusion Criteria:~* Patients unable to provide informed consent,~* emergency cases,~* seriously ill patients/unconscious patients,~* chronic renal disease,~* known inflammatory bowel disease,~* known lactose intolerance and not using lactase,~* known galactosemia,~* pregnancy,~* cows milk allergy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arginine enriched oral nutritional supplement group (Type: EXPERIMENTAL): Patients randomised to the oral nutritional supplement group will continue their normal diet. In addition, this group will commence taking oral nutritional supplement twice daily 5 days prior to surgery and continued for 4 weeks post surgery. Intake of nutritional drink will be suspended during their fasting period prior to surgery and will commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment. Patient adherence to the study protocol with the nutritional supplement regimen will be recorded daily by the patient for four the four weeks the supplement is provided.
- Control (Type: NO_INTERVENTION): This group will continue on their normal diet before and after surgery. Normal diet will be suspended during their fasting period prior to surgery and will re commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).